Last reviewed · How we verify
The Use of an Innovative Device for Therapeutic Adherence in Pediatric Asthma
The management of chronic diseases requires a constant monitoring of treatment adherence, in order to obtain an optimal disease control. However, this is often difficult to achieve, especially in pediatric age. In this sense, for asthmatic patients treated by Symbicort Turbohaler, "AstraZeneca" developed the "Turbo+", an electronic device attached to the Turbohaler, which allows to feel whether the patient does the inhalation, and to register it on a specific application. The present randomized trial aims to compare the treatment adherence between asthmatic children/adolescents aged 6-17 years treated with Symbicort Turbohaler plus Turbo+ or Symbicort Turbohaler without Turbo+.
Details
| Lead sponsor | Istituto per la Ricerca e l'Innovazione Biomedica |
|---|---|
| Phase | PHASE4 |
| Status | COMPLETED |
| Enrolment | 18 |
| Start date | Thu Jan 10 2019 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Thu Jan 23 2020 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Asthma
Interventions
- Symbicort Turbohaler plus Turbo+
- Symbicort Turbohaler without Turbo+
Countries
Italy